Nitroglycerin gel - Futura Medical

Drug Profile

Nitroglycerin gel - Futura Medical

Alternative Names: Eroxon; Glyceryl trinitrate topical gel - Futura; MED 2001; MED 2003; MED 2004; MED 2005; MED2002

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Futura Medical
  • Developer Futura Medical; MedPointe
  • Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Phase II Erectile dysfunction

Most Recent Events

  • 26 Apr 2018 Futura Medical plans the first phase III trial for Erectile dysfunction in Eastern Europe to enable selection of the two most appropriate dose strengths in the third quarter of 2018
  • 13 Mar 2018 Pharmacokinetics data from a clinical trial in Erectile dysfunction released by Futura Medical
  • 04 Jan 2018 Updated efficacy data from a phase II trial in Erectile dysfunction released by Futura Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top